Inhalation And Nasal Spray Generic Drugs Market Is Set For Lucrative Growth To 2030 Inhalation And

Rahul Nikade

Right Now

Inhalation And Nasal Spray Generic Drugs Market Is Set For Lucrative Growth To 2030

Inhalation And Nasal Spray Generic Drugs Industry

The global inhalation and nasal spray generic drugs market size is expected to reach USD 49.09 billion by 2030, registering a CAGR of 8.56% from 2025 to 2030, according to a new report by Grand View Research, Inc. New product launches, mounting prevalence of chronic respiratory diseases, growing demand for cost-effective medicines, and rising geriatric population are some of the major factors boosting the market growth.

Rising demand for cost-effective medicines and government support for the use of generics is expected to drive the demand for inhalation and nasal spray generic drugs over the forecast period. For instance, the Government of Japan has been promoting the usage of inexpensive generic drugs in order to regulate the overall pharmaceutical expenditure. This was accomplished through the execution of regulations to encourage the use of generic drugs in the past decade.

Rising number of M&A, partnerships, and collaborations among leading manufacturers including Teva Pharmaceuticals, Glenmark Specialty S.A., and Hikma Pharmaceuticals PLC is another major factor propelling the growth. For instance, in January 2022, Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals Ltd., partnered with Lotus International Pte. Ltd. for marketing Ryaltris nasal spray in Vietnam, Hong Kong, and Singapore. Under this agreement, Glenmark Specialty S.A. will manufacture and supply Ryaltris, and Lotus International Pte. Ltd. will commercialize the product. Similarly, in February 2020, Glenmark Specialty signed a licensing agreement with Hikma Pharmaceuticals PLC to commercialize Ryaltrisin in the U.S.

Extensive research in the respiratory drug discovery and generic product approvals of inhalation and nasal drugs by pharmaceutical companies are projected to fuel growth. For instance, in March 2021, Cipla Inc. received ANDA approval from the U.S. FDA for Sumatriptan Nasal Spray, a generic equivalent of Imitrex Nasal Spray indicated for migraine treatment. In addition, in May 2020, the company received Competitive Generic Therapy designation from FDA along with ANDA approval for Dihydroergotamine Mesylate Nasal Spray, a generic version of Migranal.

Gather more insights about the market drivers, restrains and growth of the Global Inhalation And Nasal Spray Generic Drugs market

Inhalation And Nasal Spray Generic Drugs Market Segments Highlights:

By drug class, the bronchodilators segment led the market with the largest revenue share of 29.84% in 2024. The growth of the bronchodilator drug segment in the global market is expected to be driven by the increasing demand for quick-relief treatments for asthma and other respiratory conditions
Based on indication, the asthma segment led the market with the largest revenue share of 42.85% in 2024.
Based on patient demographics, the adult patient segment led the market with the largest revenue share of 43.50% in 2024.
Based on end-use, the homecare segment led the market with the largest revenue share of 55.86% in 2024.
Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 56.96% in 2024.
North America inhalation and nasal spray generic drugs market dominated the inhalation and nasal spray generic drugs market with the revenue share of 38.54% in 2024.

Inhalation And Nasal Spray Generic Drugs Market Report Segmentation

Grand View Research has segmented the inhalation and nasal spray generic drugs market on the basis of drug class, indication, patient demographics, end-use, distribution channel, and region:

Inhalation And Nasal Spray Generic Drugs Drug Class Outlook (Revenue, USD Million, 2018 - 2030)